Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: A case report

Journal of Clinical Psychopharmacology

Volumn 29, Issue 5, 2009, Pages 509-511

  De Leon, Jose ^a   Kiesel, John L ^b   Fleming, Michael W ^b   Strobl, Bryan ^a  

^a EASTERN STATE HOSPITAL   (United States)

^b Central State Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATENOLOL; BENAZEPRIL; BROMOCRIPTINE; CALCIUM; CARBAMAZEPINE; GLIPIZIDE; HYDROCHLOROTHIAZIDE; LACTULOSE; LEVOTHYROXINE; LORAZEPAM; METFORMIN; NICOTINIC ACID; RANITIDINE; RISPERIDONE; SIMVASTATIN; VALPROATE SEMISODIUM; VITAMIN D;

ADULT; CARDIOVASCULAR DISEASE; CASE REPORT; CONFUSION; CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROESOPHAGEAL REFLUX; HAND TREMOR; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; LETHARGY; LETTER; LOW DRUG DOSE; MENTAL DEFICIENCY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SEIZURE; TONIC CLONIC SEIZURE; URINE INCONTINENCE; VITAMIN SUPPLEMENTATION;

ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; HUMANS; MIDDLE AGED; PROTEIN BINDING; SEIZURES; VALPROIC ACID;

EID: 70349656040     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181b4b07c     Document Type: Letter

References (12)

1. DeVane CL. Pharmacokinetics, drug interactions and tolerability of valproate. Psychopharmacol Bull. 2003;37(suppl 2): 25-42.
2. Sandson NB, Marcucci C, Bourke DL, et al. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry. 2006;163:1891-1896.
3. Bauer LA, Davis R, Wilensky A, et al. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther. 1985;37: 697-700.
4. Levy RH, Shen DD, Abbott FS, et al. Valproic acid: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:780-800.
5. Greenblatt DJ, Sellers EM, Koch-Weser J. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol. 1982;22: 259-283.
6. Benet LZ, Hoener B-A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-121.
7. DeVane CL. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol Bull. 2002;36:5-21.
8. Farrell K, Orr JM, Abbott FS, et al. The effect of acetylsalicylic acid on serum free valproate concentrations and valproate clearance in children. J Pediatr. 1982;101: 142-144.
9. Orr JM, Abbott FS, Farrell K, et al. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther. 1982;31:642-649.
10. Abbott FS, Kassam J, Orr JM, et al. The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther. 1986;40:94-100.
11. Goulden KJ, Dooley JM, Camfield PR, et al. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology. 1987;37: 1392-1394.
12. Lacy CF, Armstrong LL, Goldman MP, et al. Drug Information Handbook. 15th ed. Hudson, OH: Lexi-Comp; 2007.